Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.22 USD
-0.02 (-1.61%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.28 +0.06 (4.92%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Aclaris Therapeutics (ACRS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1.84 | $3.00 | $1.00 | 48.39% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Aclaris Therapeutics comes to $1.84. The forecasts range from a low of $1.00 to a high of $3.00. The average price target represents an increase of 48.39% from the last closing price of $1.24.
Analyst Price Targets (5 )
Broker Rating
Aclaris Therapeutics currently has an average brokerage recommendation (ABR) of 2.78 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 2.78 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, one is Strong Buy, representing 11.11% of all recommendations. A month ago, Strong Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.78 | 2.78 | 2.78 | 2.78 | 2.78 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/8/2024 | SVB Securities | Thomas J Smith | Hold | Hold |
5/8/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Hold | Hold |
5/8/2024 | Piper Sandler | Christopher Raymond | Hold | Hold |
4/16/2024 | Cantor Fitzgerald & Co | Louise Chen | Hold | Hold |
4/2/2024 | Not Identified | Not Identified | Hold | Hold |
1/19/2024 | BTIG | Julian Harrison | Hold | Hold |
11/13/2023 | William Blair | Timothy F Lugo | Strong Buy | Hold |
10/3/2023 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.78 |
ABR (Last week) | 2.78 |
# of Recs in ABR | 9 |
Average Target Price | $1.84 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 105 of 253 |
Current Quarter EPS Est: | -0.19 |